Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The University of Western Australia | OTHER |
| Telethon Kids Institute | OTHER |
| Western Australian Country Health Service | UNKNOWN |
| Northern Territory Government of Australia |
Not provided
Not provided
Not provided
Not provided
The Non-Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and AnteNatal clinics (NEARER SCAN) study is a co-designed, implementation research project that will improve equitable access to culturally safe, best quality care for Rheumatic Heart Disease (RHD) in high-burden Aboriginal and Torres Strait Islander communities in Australia, and in Timor-Leste. The research addresses an area of unmet need, using novel technologies and embedding them in health practice, to enhance and accelerate diagnosis of RHD outside acute health settings and improve outcomes. The study will be conducted in partnership with community leaders and local partners.
This study titled 'Non-Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and AnteNatal clinics' (NEARER SCAN; "LENO BESIK" in Tetum) aims to co-design, implement and evaluate a task-sharing approach to echocardiographic screening for early detection and management of rheumatic heart disease (RHD) in high-risk settings in Australia and Timor-Leste.
Specific objectives include:
Local primary health clinic staff will be trained to perform focused echocardiography using hand-carried ultrasound (HCU) devices employing the 'Single Parasternal Long Axis view with a Sweep of the Heart' (SPLASH) technique. The acquired images will be interpreted by experts (cardiologists and cardiac sonographers) remotely from the site of acquisition. Approximately 1500 children and pregnant women will be screened across high-risk communities in Australia and Timor Leste, over an 18 month period.
A mixed-methods effectiveness-implementation study design will be used to evaluate the implementation of an intervention designed to achieve early detection and management of RHD in high-risk populations. An implementation strategy will be co-designed at each site with the local community and participating primary healthcare (PHC) service, incorporating non-adaptable elements of the intervention, and mapped onto a Theory of Change framework. Co-design, implementation and evaluation will occur simultaneously, and a Type 2 hybrid design study will be used to evaluate both the implementation strategies and the clinical effectiveness of the intervention. The clinical effectiveness will be assessed as the change in the proportion of the at-risk population that received secondary prophylaxis by the end of the study compared to baseline. Program implementation will be evaluated with a realist evaluation to explain under what circumstances the program is successfully integrated into routine service delivery. Data informing evaluation will include numbers of normal, abnormal, and uninterpretable SPLASH echocardiograms obtained, numbers of participants progressing through the cascade of care, augmented by qualitative data from interviews conducted with staff and participants, and costs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Participant receiving echocardiography screening. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SPLASH echocardiography screening | Diagnostic Test | Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in proportion receiving secondary antibiotic prophylaxis | The change in proportion of the at-risk population receiving secondary antibiotic prophylaxis at the end of the study as compared to baseline | 18 months from commencement of study |
| Measure | Description | Time Frame |
|---|---|---|
| Full echocardiogram following screening echocardiogram | Proportion of people with an abnormal or uninterpretable screening echocardiogram who get a full diagnostic echocardiogram within 3 months and receive a diagnosis. | 3 months from screening echocardiogram |
| Proportion of people diagnosed with RHD who are retained in care |
Not provided
Inclusion Criteria in Australia:
Inclusion criteria for Timor-Leste:
Exclusion criteria for Australia and Timor-Leste:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Joshua R Francis, MBBS | Contact | +61423528381 | josh.francis@menzies.edu.au | |
| James A Marangou, MBBS | Contact | +61412277527 | james.marangou@menzies.edu.au |
| Name | Affiliation | Role |
|---|---|---|
| Joshua R Francis, MBBS | Menzies School of Health Research | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39424380 | Derived | Jones B, Marangou J, Yan J, Ralph A, Mitchell A, Kaethner A, Remenyi B, Wade V, Katzenellenbogen JM, Monteiro AF, Cannon JW, Howard NJ, Gilles M, Haynes E, Seixas H, Maurays J, Neave J, Pears C, Engelman D, Canuto K, Steer A, Unger H, Bailey M, Tanesi M, Amaral S, Neto H, Stewart M, Burgess P, Brown A, Currie BJ, Hillis G, Morris P, Simon D, Wheaton G, Williamson J, de Dassel J, Slota-Kan S, Carapetis J, English M, Nagraj S, Francis JR. NEARER SCAN (LENO BESIK) evaluation of a task-sharing echocardiographic active case finding programme for rheumatic heart disease in Australia and Timor-Leste: protocol for a hybrid type II effectiveness-implementation study. BMJ Open. 2024 Oct 18;14(10):e083467. doi: 10.1136/bmjopen-2023-083467. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012214 | Rheumatic Heart Disease |
| ID | Term |
|---|---|
| D012213 | Rheumatic Fever |
| D013290 | Streptococcal Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
| OTHER_GOV |
| Timor-Leste Ministry of Health | UNKNOWN |
| Miwatj Health Aboriginal Corporation | UNKNOWN |
| Mala'la Health Service Aboriginal Corporation | UNKNOWN |
| Pilbara Aboriginal Health Alliance | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Proportion of people diagnosed during study period with RHD who receive guideline-based care by local health service |
| 18 months from commencement of study |
| Secondary antibiotic prophylaxis prescription and adherence | Proportion of people prescribed secondary prophylaxis who are achieving >= 80% adherence in a 12 months period from time of diagnosis or the end of the study, whichever is longer. | 12 months from time of diagnosis or at end of the study (which ever is longer). |
| Maternal morbidity and mortality outcomes | Description of maternal morbidity and mortality in pregnant women diagnosed with RHD on echocardiographic screening. This will be reported in absolute numbers and percentage of study population. Morbidity will include cardiac complications (heart failure, arrhythmia, aborted sudden cardiac death, acute myocardial infarction), need for obstetric intervention including emergency cesarean section, intensive care admission, other obstetric complications. | Within 6 weeks of the individual's post-partum period |
| Prevalence of rheumatic heart disease within the screened population | Prevalence of RHD in screened population based on echocardiographic diagnosis | 18 months from commencement of study |
| Rheumatic valvular heart disease severity (mild, moderate or severe) within the screening population based on echocardiographic diagnosis | Description of severity of RHD in screened population. This will include proportions of mild, moderate and severe valve disease. | 18 months from commencement of study |
| Neonatal morbidity and mortality outcomes | Description of neonatal morbidity and mortality outcomes for the pregnant women diagnosed with RHD. This will be reported as absolute numbers and percentage of study population. Morbidity will include need for admission to neonatal intensive care. | Within 6 weeks post-partum |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |